Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 905 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... February 16, 2023 How radiotherapy became a lifesaver – from X-rays to the proton... July 8, 2022 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... June 25, 2025 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Load more HOT NEWS FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Health inequalities: breaking down barriers to cancer screening The European Parliament’s Reports Include Several ESMO Asks and Materially Strengthen... Antibody Drug Ejects Problematic Proteins from Cancer Cells
